[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"knee-cartilage-lesions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:knee-cartilage-lesions":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100639251","the-effect-of-lipedema-on-knee-osteoarthritis-100639251",false,"NCT07575555","The Effect of Lipedema on Knee Osteoarthritis","The Effect of Lipedema on Knee Osteoarthritis: A Cross-Sectional Analysis of Clinical Symptoms and Ultrasonographic Findings","Inclusion Criteria:\n\nAll participants (Group 1 + Group 2)\n\n* Women aged 30-65\n* With a clinical and radiological diagnosis of knee osteoarthritis\n* Who agreed to participate in the study\n\nGroup 1 (knee osteoarthritis with lipedema):\n\n* Patients who meet the Wold criteria for a clinical diagnosis of lipedema\n* An increase in subcutaneous fat thickness confirmed by ultrasound\n\nGroup 2 (knee osteoarthritis without lipedema):\n\n* No diagnosis of lipedema\n* Exclusion of lymphedema and venous diseases\n\nExclusion Criteria:\n\n* Inflammatory arthritis\n* History of knee surgery\n* Intra-articular injection within the past 6 months\n* Acute trauma\n* Systemic connective tissue disease\n* Severe venous insufficiency or lymphedema\n* History of malignancy\n* Use of gabapentinoids\u002FSNRIs\u002FSSRIs due to fibromyalgia or psychiatric illness\n* Severe cognitive impairment or communication problems that would prevent participation in the study\n* Pregnancy\n* Participants who were informed about the study and refused to participate","FEMALE","30 Years","65 Years",{"count":20,"type":21},76,"ESTIMATED","1 Day","OBSERVATIONAL","This study will be one of the few to examine the effect of lipedema on knee osteoarthritis in a comparative manner with a control group within the same osteoarthritis context. Although the relationship between obesity and osteoarthritis has been extensively studied in the literature, the effect of specific adipose tissue pathologies, such as lipedema, on osteoarthritis has not been sufficiently investigated. This study aims to demonstrate the independent effect of lipedema on osteoarthritis, evaluate clinical and ultrasonographic parameters together, and contribute to early diagnosis and targeted rehabilitation strategies.",[26,27,28,29,30,31,32,33],"Lipedema","Knee Osteoarthritis","Knee Acute and Chronic Pain","Knee","Knee Arthritis Osteoarthritis","Knee Arthropathy","Knee Cartilage Defects","Knee Cartilage Lesions",[35,36,37,38],"lipedema","knee osteoarthritis","knee joint","knee","NOT_YET_RECRUITING","2026-05-03",{"date":42,"type":43},"2026-05-08","ACTUAL",{"date":45,"type":21},"2026-07-15",{"date":47,"type":21},"2027-08-15",{"name":49,"class":50},"Izmir Democracy University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100612123","nanochon-chondrograft-first-in-human-fih-early-feasibility-study-efs---canada-100612123","NCT07249489","Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada","A First in Human (FIH) Early Feasibility Study (EFS) to Evaluate the Safety and Performance of the Nanochon Chondrograft™ Implant for Re-surfacing of Cartilage Lesions","Inclusion Criteria:\n\n* Male or female ≥22 years and ≤ 60 years of age\n* MRI knee evaluation completed within 6 months prior to enrollment\n* Participant must be able to read and speak English\n* Participant must voluntarily sign the REB approved informed consent form (ICF)\n\nExclusion Criteria:\n\n* Any known systemic cartilage and\u002For bone disorder, such as, but not limited to, osteoporosis, chondrodysplasia or osteogenesis imperfecta\n* Requires bilateral knee surgery\n* Pregnancy, planning to become pregnant or breast feeding\n* Any significant illness (metastasis cancer of any type) that decreases the probability of the participant's survival to 12 months\n* Known insulin dependent diabetes mellitus\n* Steroid treatment (oral or IV) within the past 6 months\n* Participant is:\n\n  1. receiving workman's compensation\n  2. receiving prescription narcotic medication\n  3. active with litigation relating to musculoskeletal injuries or disorders\n  4. a prisoner or pending incarceration\n* Comorbidities that could impact study participation or results (e.g., autoimmune disorder, HIV, neuropathic pain or fibromyalgia, restless leg syndrome, active infection, or pain requiring chronic pain management), in the opinion of the investigator at the time of enrollment\n* Significant psychiatric disorders (e.g., major depression, anxiety disorders, bipolar disorder, and schizophrenia)\n* Substance and\u002For alcohol dependence and\u002For abuse based on clinical history, physical exam and participant presentation\n* Current participation in another drug or device study that, in the opinion of the investigator at the time of enrollment, would interfere with participation in this study\n* Participant has claustrophobia or implanted metallic devices (e.g., cardiac pacemakers, insulin pumps, nerve stimulators), medically implanted clips or other electronically, magnetically or mechanically activated implants that would contraindicate undergoing an MRI\n* Known allergy or hypersensitivity to any investigational device materials.","ALL","22 Years","60 Years",{"count":63,"type":21},10,"INTERVENTIONAL",[66],"NA","The goal of this First in Human study is to learn if the Nanochon Chondrograft Implant is a safe primary surgical treatment for participants with cartilage lesions in the knee. This study will include males and females between the ages of 22 and 60.",[33],[70,71,72,73],"Knee cartilage lesions","Medial femoral condyle lesion","Lateral femoral condyle lesion","Trochlea articular cartilage lesion","RECRUITING","2026-04-20",{"date":77,"type":43},"2026-04-22",{"date":79,"type":21},"2026-04",{"date":81,"type":21},"2027-08",{"name":83,"class":84},"Nanochon, Inc.","INDUSTRY",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":57,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":92,"targetDuration":4,"studyType":64,"phases":94,"briefSummary":67,"conditions":95,"keywords":96,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":51},"100634630","nanochon-chondrograft-first-in-human-fih-early-feasibility-study-efs---panama-100634630","NCT07542184","Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Panama","Inclusion Criteria:\n\n* Male or female ≥22 years and ≤ 60 years of age\n* MRI knee evaluation completed within 6 months prior to enrollment\n* Participant must be able to read and speak English and\u002For Spanish\n* Participant must voluntarily sign the REB approved informed consent form (ICF)\n\nExclusion Criteria:\n\n* Any known systemic cartilage and\u002For bone disorder, such as, but not limited to, osteoporosis, chondrodysplasia or osteogenesis imperfecta\n* Requires bilateral knee surgery\n* Pregnancy, planning to become pregnant or breast feeding\n* Any significant illness (metastasis cancer of any type) that decreases the probability of the participant's survival to 12 months\n* Known insulin dependent diabetes mellitus\n* Steroid treatment (oral or IV) within the past 6 months\n\nParticipant is:\n\n1. receiving workman's compensation\n2. receiving prescription narcotic medication\n3. active with litigation relating to musculoskeletal injuries or disorders\n4. a prisoner or pending incarceration\n\n   * Comorbidities that could impact study participation or results (e.g., autoimmune disorder, HIV, neuropathic pain or fibromyalgia, restless leg syndrome, active infection, or pain requiring chronic pain management), in the opinion of the investigator at the time of enrollment\n   * Significant psychiatric disorders (e.g., major depression, anxiety disorders, bipolar disorder, and schizophrenia)\n   * Substance and\u002For alcohol dependence and\u002For abuse based on clinical history, physical exam and participant presentation\n   * Current participation in another drug or device study that, in the opinion of the investigator at the time of enrollment, would interfere with participation in this study\n   * Participant has claustrophobia or implanted metallic devices (e.g., cardiac pacemakers, insulin pumps, nerve stimulators), medically implanted clips or other electronically, magnetically or mechanically activated implants that would contraindicate undergoing an MRI\n   * Known allergy or hypersensitivity to any investigational device materials.",{"count":93,"type":21},5,[66],[33],[70,71,72,73],"2026-04-14",{"date":99,"type":43},"2026-04-21",{"date":101,"type":21},"2026-05",{"date":81,"type":21},{"name":83,"class":84}]